BIOXYTRAN, INC. Files 8-K: Financial Reporting Concerns
Ticker: BIXT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1445815
| Field | Detail |
|---|---|
| Company | Bioxytran, Inc (BIXT) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 B, $0.001, $212,458, $19,935, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, restatement-risk
TL;DR
BIOXYTRAN 8-K: They might have messed up old financials. Big yikes.
AI Summary
On January 13, 2025, BIOXYTRAN, INC. filed an 8-K report. The filing indicates a change in the company's reporting status, specifically related to Item 4.02, which concerns Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. This suggests potential issues with past financial reporting.
Why It Matters
This filing signals potential inaccuracies in BIOXYTRAN's past financial statements, which could impact investor confidence and require restatements.
Risk Assessment
Risk Level: medium — A non-reliance statement on financial reports can indicate significant accounting issues that may require restatements and negatively impact the stock price.
Key Players & Entities
- BIOXYTRAN, INC. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Item 4.02 (filing_item) — Non-Reliance on Previously Issued Financial Statements
FAQ
What specific financial statements are affected by the non-reliance statement?
The filing does not specify which particular financial statements are affected, only that there is a non-reliance on previously issued financial statements or a related audit report or completed interim review.
What is the reason for BIOXYTRAN, INC.'s non-reliance on its previously issued financial statements?
The filing does not provide the specific reasons for the non-reliance on previously issued financial statements.
When was the decision made regarding the non-reliance on financial statements?
The filing reports this event as of January 13, 2025, which is the date of the earliest event reported.
Has BIOXYTRAN, INC. previously filed an 8-K for similar reasons?
This filing does not contain information about previous 8-K filings for similar reasons.
What is the Commission File Number for BIOXYTRAN, INC.?
The Commission File Number for BIOXYTRAN, INC. is 001-35027.
Filing Stats: 2,032 words · 8 min read · ~7 pages · Grade level 15.2 · Accepted 2025-01-13 11:44:46
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BIXT OTCQB Indicate by check mark whe
- $0.001 — Stockholders' equity Preferred stock, $0.001 par value — — — — — — Adjustmen
- $212,458 — xemption in Rule 3(a)(9), resulted in a $212,458 increase to the Loss of issuance line i
- $19,935 — ge Exemption in Rule 701, resulted in a $19,935 reduction to the Compensation Expense l
- $300,000 — nce sheet date. In 2022 the amount of $300,000 R&D expense was reclassified to other i
- $30,000 — arch 31, 2023. A private placement of $30,000 was incorrectly booked as stock subscri
- $4,773 — income/expense reducing the result with $4,773 at December 31, 2022, and was offset to
- $1,744 — et against liabilities for an amount of $1,744 for the year ended December 31, 2023, a
- $4,429 — legal services reduced the result with ($4,429) for the year ended December 31, 2022,
- $5,262 — year ended December 31, 2022, and with ($5,262) for the year ended on December 31, 202
Filing Documents
- form8-k.htm (8-K) — 108KB
- 0001493152-25-001891.txt ( ) — 283KB
- bixt-20250113.xsd (EX-101.SCH) — 3KB
- bixt-20250113_lab.xml (EX-101.LAB) — 33KB
- bixt-20250113_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOXYTRAN, INC. By: /s/ David Platt, Ph.D. David Platt, Ph.D., its Chief Executive Officer Date: January 13, 2025